Pfizer’s COVID-19 pill Paxlovid won another vote of confidence from U.S. health advisers Thursday, clearing the way for its full regulatory approval by the Food and Drug Administration.
A panel of outside experts voted 16-1 that Paxlovid remains a safe and effective treatment for high-risk adults with COVID-19 who are more likely to face hospitalization and death due to the virus.
The panel’s positive vote was widely expected, given that Paxlovid has been the go-to treatment against COVID-19, especially since an entire group of antibody drugs has been sidelined as the virus mutated.The agency asked its panel of independent medical experts to address several lingering questions involving Paxlovid, including which people currently benefit from treatment and whether the drug plays a role in cases of COVID-19 rebound.
The federal government has purchased more than 20 million doses of Paxlovid and encouraged health professionals to prescribe it aggressively to help prevent severe COVID-19. But that’s led to concerns of overprescribing and questions of whether some patients are needlessly getting the drug.
Indonesia Berita Terbaru, Indonesia Berita utama
Similar News:Anda juga dapat membaca berita serupa dengan ini yang kami kumpulkan dari sumber berita lain.
No clear association between Paxlovid and COVID-19 rebound, FDA saysAn FDA analysis did not find a clear association between the COVID-19 antiviral drug Paxlovid and illness rebound, the FDA said in a new report.
Baca lebih lajut »
Paxlovid not linked to COVID rebound, FDA saysClinical trial data has concluded that there is no clear association with a COVID-19 rebound.
Baca lebih lajut »
Paxlovid not linked to COVID rebound, FDA saysThe FDA gave the COVID-19 anti-viral emergency use authorization in 2021 for treating mild to moderate illness in high-risk adults.
Baca lebih lajut »
COVID-19 pill Paxlovid moves closer to full FDA approvalU.S. health advisersare backing the continued use of Pfizer’s COVID-19 pill Paxlovid, saying it remains an important option for adults at high risk of severe illness
Baca lebih lajut »
COVID-19 pill Paxlovid moves closer to full FDA approvalPfizer’s COVID-19 pill Paxlovid won another vote of confidence from U.S. health advisers, clearing the way for its full approval by the FDA. The medication has been used by millions of Americans since it was granted emergency use authorization in 2021.
Baca lebih lajut »
COVID-19 pill Paxlovid moves closer to full FDA approvalU.S. health advisors are backing the continued use of Pfizer’s COVID-19 pill Paxlovid, saying it remains an important option for adults at high risk of severe illness.
Baca lebih lajut »